網膜静脈分枝閉塞症に伴う黄斑浮腫に対するベバシズマブ硝子体内注入の中期成績

Mid-term outcome of intravitreal bevacizumab for branch retinal vein occlusion with macular edema

要約　目的：網膜静脈分枝閉塞症（BRVO）に対するベバシズマブ硝子体注射の8か月以上の経過の報告。症例と方法：黄斑浮腫があるBRVO 33例33眼を対象とした。年齢は44～78歳（平均63歳）である。ベバシズマブを投与し，8～49か月（平均15か月）の経過を追った。視力はlogMARで評価した。結果：平均視力は術前0.47，最終診察時0.23で，有意に改善した（p＜0.001）。光干渉断層計（OCT）で測定した網膜中心窩厚の平均値は，術前552.7μm，最終診察時336.8μmで，有意に改善した（p＜0.001）。結論：BRVOに併発した黄斑浮腫は自然寛解することがあるが，発症後早期にベバシズマブの硝子体注射をすることで，良好な視力が維持できる可能性がある。

Abstract.　Purpose：To report the outcome of intravitreal injection of bevacizumab for branch retinal vein occlusion（BRVO）with macular edema. Cases and Method：This study was made on 33 eyes of 33 patients who received intravitreal bevacizumab for BRVO with macular edema. The age ranged from 44 to 78 years,average 63 years. Cases were followed up for 8 to 49 months,average 15 months,after treatment. Visual acuity was evaluated in terms of logMAR. Results：Visual acuity averaged 0.47 before treatment and 0.23 at the last visit. The difference was significant（p＜0.001）. Central retinal thickness,as measured by optical cohererence tomography（OCT）,averaged 552.7μm before treatment and 336.8μm at the final visit. The difference was significant（p＜0.001）. Conclusion：While macular edema secondary to BRVO may spontaneously resolve,intravitreal bevacizumab may result in maintaining fair visual acuity when applied during the early stage after onset.